Some residents, taking antipsychotics, were referred to a Psychiatry of Old Age Services (POAS) JQ1 consultant and their team who undertook a detailed review of antipsychotics with an aim to reduce inappropriate use. Following the review/MDT, options about which medicines should be stopped, changed or started were discussed with the resident and/or the family (in cases where the resident had no capacity to make informed decisions). The following questions were asked and discussed: Is the medication still needed i.e. currently treating or preventing disease? Does

the medicine still have benefits taking into consideration co-morbidities (e.g. palliative care)? Are there any medications not prescribed that the patient should be taking? Following any changes, residents were followed up monthly and post-review events were documented (i.e. any adverse event that was attributed to actions taken at the review). This abstract presents results from the first three (of twelve) care homes reviewed as part this project. Savings calculations were for medicines stopped/started and were based on the average savings from the pilot study (£32 per resident per month).2 Interim data: 86 residents have been reviewed over 16 sessions. They

were taking 749 medicines at the beginning of the review (8.7 medicines per resident). In total, 385 interventions were made including 241 medicines being stopped and 19 medicines started. At the end of Ganetespib solubility dmso the review, residents were taking 527 medicines (6.1 medicines per resident), resulting in a net reduction of 2.6 medicines per resident. There were 15 referrals to the POAS service. Etomidate Follow up for 44 residents has been undertaken and there have been 6 minor adverse events reported (e.g. rash following stopping antihistamine). Estimated monthly savings for 86 patients was £2,752, from medicines stopped/started. Other costs (pharmacist/GP/consultant time, hospital admissions) have yet to be determined, but will be

taken into consideration in an overall evaluation of the project. Through these reviews, residents were only prescribed medicines that were beneficial, appropriate and evidence based, ensuring full participation of the resident/family in any decisions made, with medicines deemed inappropriate or unnecessary being discontinued. Follow-up identified few minor events from discontinuing over two hundred medicines; most patients can safely stop taking medicines they no longer require. Limitations of this project include lack of overall costs of providing this service, the impact on longer term outcomes (e.g. hospitalisations) and the assumption that savings from this project will mirror pilot data; these data are being collected for future analysis.